(Z)3,4,5,4′-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Fan, Xing Xing ^a   Yao, Xiao Jun ^a   Xu, Su Wei ^a   Wong, Vincent Kam Wai ^a   He, Jian Xing ^b   Ding, Jian ^c   Xue, Wei Wei ^e   Mujtaba, Tahira ^f   Michelangeli, Francesco ^f   Huang, Min ^c   Huang, Jun ^b   Xiao, Da Kai ^b   Jiang, Ze Bo ^a   Zhou, Yan Ling ^a   Kin Ting Kam, Richard ^d   Liu, Liang ^a   Lai Han Leung, Elaine ^a  

^a MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^d Chinese University of Hong Kong   (Hong Kong)

^e CHONGQING UNIVERSITY   (China)

^f UNIVERSITY OF CHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4,5,4'-TETRAMETHOXYSTILBENE; ADENYLATE KINASE; ANTINEOPLASTIC AGENT; CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE; STILBENE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; HUMAN; METABOLISM; TUMOR CELL LINE;

ADENYLATE KINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STILBENES;

EID: 84946771826     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16348     Document Type: Article

References (48)

1. Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F.& Wong, K.K.Non-small-cell lung cancers: A heterogeneous set of diseases.Nat Rev Cancer 14, 535-546 (2014).
2. Fan, X.X.et al.Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.Molecules 19, 3508-3522 (2014).
3. An, X.et al.BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review.Leuk Res 34, 1255-1268 (2010).
4. Sordella, R., Bell, D.W., Haber, D.A.& Settleman, J.Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Science 305, 1163-1167 (2004).
5. Pao, W.et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PLoS Med 2, e73 (2005).
6. Brisdelli, F., D'Andrea, G.& Bozzi, A.Resveratrol: A natural polyphenol with multiple chemopreventive properties.Curr Drug Metab 10, 530-546 (2009).
7. Catalgol, B., Batirel, S., Taga, Y.& Ozer, N.K.Resveratrol: French paradox revisited.Front Pharmacol 3, 141 (2012).
8. Pearson, K.J.et al.Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.Cell Metab 8, 157-168 (2008).
9. Hua, J.et al.Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice.Invest Ophthalmol Vis Sci 52, 2809-2816 (2011).
10. Baur, J.A.et al.Resveratrol improves health and survival of mice on a high-calorie diet.Nature 444, 337-342 (2006).
11. Bishayee, A.Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.Cancer Prev Res (Phila) 2, 409-418 (2009).
12. Luo, H., Yang, A., Schulte, B.A., Wargovich, M.J.& Wang, G.Y.Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage.PLoS One 8, e60065 (2013).
13. Whyte, L., Huang, Y.Y., Torres, K.& Mehta, R.G.Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses.Cancer Res 67, 12007-12017 (2007).
14. Sale, S.et al.Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3, 4, 5, 4?-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in humanderived colon cancer cells.Int J Cancer 115, 194-201 (2005).
15. Piotrowska, H.et al.Resveratrol analogue 3, 4, 4?, 5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells.Toxicol Appl Pharmacol 263, 53-60 (2012).
16. Piotrowska, H.et al.Different susceptibility of colon cancer DLD-1 and LOVO cell lines to apoptosis induced by DMU-212, a synthetic resveratrol analogue.Toxicol In Vitro 27, 2127-2134 (2013).
17. Wong, V.K.et al.Saikosaponin-d, a novel SERCA inhibitor, induces autophagic cell death in apoptosis-defective cells.Cell Death Dis 4, e720 (2013).
18. Harr, M.W.& Distelhorst, C.W.Apoptosis and autophagy: decoding calcium signals that mediate life or death.Cold Spring Harb Perspect Biol 2, a005579 (2010).
19. Woods, A.et al.Ca2+ /calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells.Cell Metab 2, 21-33 (2005).
20. Shi, W.Y.et al.Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.Cell Death Dis 3, e275 (2012).
21. Dalby, K.N., Tekedereli, I., Lopez-Berestein, G.& Ozpolat, B.Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer.Autophagy 6, 322-329 (2010).
22. Turcotte, S.& Giaccia, A.J.Targeting cancer cells through autophagy for anticancer therapy.Curr Opin Cell Biol 22, 246-251 (2010).
23. Klionsky, D.J.et al.Guidelines for the use and interpretation of assays for monitoring autophagy.Autophagy 8, 445-544 (2012).
24. Fujishita, T., Aoki, M.& Taketo, M.M.JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Delta716) mice.Gastroenterology 140, 1556-1563 e1556 (2011).
25. Fan, Q.W.et al.EGFR signals to mTOR through PKC and independently of Akt in glioma.Sci Signal 2, ra4 (2009).
26. Sharma, S.V., Bell, D.W., Settleman, J.& Haber, D.A.Epidermal growth factor receptor mutations in lung cancer.Nature reviews.Cancer 7, 169-181 (2007).
27. Aris P.Cancer multidrug resistance.Nat Biotechnol 18 Suppl, IT18-20 (2000).
28. Zhou, J.X.et al.Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.Ann Oncol 24, 1319-1325 (2013).
29. Arcila, M.E.et al.Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.Clin Cancer Res 17, 1169-1180 (2011).
30. Walter, A.O.et al.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.Cancer Discov 3, 1404-1415 (2013).
31. Bryant, J.A., Finn, R.S., Slamon, D.J., Cloughesy, T.F.& Charles, A.C.EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.Cancer Biol Ther 3, 1243-1249 (2004).
32. Steelman, L.S.et al.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Aging (Albany NY) 3, 192-222 (2011).
33. Borders, E.B., Bivona, C.& Medina, P.J.Mammalian target of rapamycin: biological function and target for novel anticancer agents.Am J Health Syst Pharm 67, 2095-2106 (2010).
34. Laplante, M.& Sabatini, D.M.mTOR signaling in growth control and disease.Cell 149, 274-293 (2012).
35. Dibble, C.C.& Manning, B.D.Signal integration by mTORC1 coordinates nutrient input with biosynthetic output.Nat Cell Biol 15, 555-564 (2013).
36. Reiling, J.H.& Sabatini, D.M.Stress and mTORture signaling.Oncogene 25, 6373-6383 (2006).
37. Jewell, J.L., Russell, R.C.& Guan, K.L.Amino acid signalling upstream of mTOR.Nat Rev Mol Cell Biol 14, 133-139 (2013).
38. Hay, N.& Sonenberg, N.Upstream and downstream of mTOR.Genes Dev 18, 1926-1945 (2004).
39. Faivre, S., Kroemer, G.& Raymond, E.Current development of mTOR inhibitors as anticancer agents.Nat Rev Drug Discov 5, 671-688 (2006).
40. Benjamin, D., Colombi, M., Moroni, C.& Hall, M.N.Rapamycin passes the torch: A new generation of mTOR inhibitors.Nat Rev Drug Discov 10, 868-880 (2011).
41. Kaminski, G.A.F.R.A., Tirado-Rives, J.& Jorgensen, W.L.Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides.J.Phys.Chem.B 105, 6474-6487 (2001).
42. Obara, K.et al.Structural role of countertransport revealed in Ca(2+) pump crystal structure in the absence of Ca(2+).Proc Natl Acad Sci U S A 102, 14489-14496 (2005).
43. Kollman, P.A.et al.Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models.Acc Chem Res 33, 889-897 (2000).
44. Liu, M.J., Wang, Z., Ju, Y., Wong, R.N.& Wu, Q.Y.Diosgenin induces cell cycle arrest and apoptosis in human leukemia K562 cells with the disruption of Ca2+ homeostasis.Cancer Chemother Pharmacol 55, 79-90 (2005).
45. Michelangeli, F.& Munkonge, F.M.Methods of reconstitution of the purified sarcoplasmic reticulum (Ca(2+)-Mg2+)-ATPase using bile salt detergents to form membranes of defined lipid to protein ratios or sealed vesicles.Anal Biochem 194, 231-236 (1991).
46. Michelangeli, F., Colyer, J., East, J.M.& Lee, A.G.Effect of pH on the activity of the Ca2+ + Mg2(+)-activated ATPase of sarcoplasmic reticulum.Biochem J 267, 423-429 (1990).
47. Mezna, M.& Michelangeli, F.The effects of inositol 1, 4, 5-trisphosphate (InsP3) analogues on the transient kinetics of Ca2+ release from cerebellar microsomes.InsP3 analogues act as partial agonists.J Biol Chem 271, 31818-31823 (1996).
48. Longland, C.L.et al.Biochemical mechanisms of calcium mobilisation induced by mastoparan and chimeric hormonemastoparan constructs.Cell Calcium 24, 27-34 (1998).